Health Care & Life Sciences » Biotechnology | SIGA Technologies Inc.

SIGA Technologies Inc. | Income Statement

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Sales/Revenue
5,519.30
3,139.80
8,175.90
14,987.60
12,269.00
477,053.80
SG&A Expense
28,059.40
23,990.20
24,474.30
32,566.00
28,850.60
25,860.10
EBIT
23,003.20
-
16,545.80
18,662.10
17,623.80
355,135.30
Unusual Expense
586.70
190,278.20
22,219.00
5,295.70
5,964.20
6,958.50
Non Operating Income/Expense
1.50
1.10
42.20
1,661.90
16.80
78,941
Interest Expense
1,207.30
455.80
266.70
14,064.40
14,758.10
15,478.20
Pretax Income
24,795.80
211,934.90
38,989.30
39,684.10
38,329.30
411,639.60
Income Tax
7,618.40
53,528.30
462.00
13.90
2,093.80
10,168.30
Consolidated Net Income
17,177.30
265,463.10
39,451.30
39,698.00
36,235.50
421,807.80
Net Income
17,177.30
265,463.10
39,451.30
39,698.00
36,235.50
421,807.80
Net Income After Extraordinaries
17,177.30
265,463.10
39,451.30
39,698.00
36,235.50
421,807.80
Net Income Available to Common
17,177.30
265,463.10
39,451.30
39,698.00
36,235.50
421,807.80
EPS (Basic)
0.33
4.97
0.73
0.69
0.46
5.18
Basic Shares Outstanding
52,368.80
53,419.70
53,777.70
57,188.50
78,874.50
79,923.30
EPS (Diluted)
0.33
4.97
0.73
0.69
0.46
5.18
Diluted Shares Outstanding
52,368.80
53,419.70
53,777.70
57,188.50
78,874.50
82,708.50
EBITDA
22,540.10
20,850.40
16,298.40
18,487.80
17,491.60
355,204.90
Other Operating Expense
-
-
-
909.40
910.00
789.50

About SIGA Technologies

View Profile
Address
31 East 62nd Street
New York New York 10065
United States
Employees -
Website http://www.siga.com
Updated 07/08/2019
SIGA Technologies, Inc. engages in the development and commercialization of solutions for serious unmet medical needs and biothreats. The company develops therapeutic solutions for lethal pathogens including smallpox, Ebola, dengue, Lassa fever, and other dangerous viruses. It offers an orally administered antiviral drug that targets orthopoxviruses under the TPOXX brand.